These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19719454)

  • 21. Immunotherapy in prostate cancer: emerging strategies against a formidable foe.
    Bilusic M; Heery C; Madan RA
    Vaccine; 2011 Sep; 29(38):6485-97. PubMed ID: 21741424
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer.
    Aragon-Ching JB; Williams KM; Gulley JL
    Front Biosci; 2007 Sep; 12():4957-71. PubMed ID: 17569623
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer immunotherapy: sipuleucel-T and beyond.
    Hammerstrom AE; Cauley DH; Atkinson BJ; Sharma P
    Pharmacotherapy; 2011 Aug; 31(8):813-28. PubMed ID: 21923608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer vaccines: current status and future potential.
    Doehn C; Böhmer T; Kausch I; Sommerauer M; Jocham D
    BioDrugs; 2008; 22(2):71-84. PubMed ID: 18345705
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunotherapy in genitourinary malignancies.
    Wattenberg MM; Fong L; Madan RA; Gulley JL
    Curr Opin Urol; 2016 Nov; 26(6):501-7. PubMed ID: 27471994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapeutics in development for prostate cancer.
    Harzstark AL; Small EJ
    Oncologist; 2009 Apr; 14(4):391-8. PubMed ID: 19342474
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical and clinical development of DNA vaccines for prostate cancer.
    Colluru VT; Johnson LE; Olson BM; McNeel DG
    Urol Oncol; 2016 Apr; 34(4):193-204. PubMed ID: 24332642
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications.
    Singh BH; Gulley JL
    Asian J Androl; 2014; 16(3):364-71. PubMed ID: 24435055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.
    Gatti-Mays ME; Redman JM; Collins JM; Bilusic M
    Hum Vaccin Immunother; 2017 Nov; 13(11):2561-2574. PubMed ID: 28857666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemotherapy and immunotherapy combination in advanced prostate cancer.
    Slovin S
    Clin Adv Hematol Oncol; 2012 Feb; 10(2):90-100. PubMed ID: 22402350
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on prostate cancer vaccines.
    Drake CG
    Cancer J; 2011; 17(5):294-9. PubMed ID: 21952278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combining immunological and androgen-directed approaches: an emerging concept in prostate cancer immunotherapy.
    Antonarakis ES; Drake CG
    Curr Opin Oncol; 2012 May; 24(3):258-65. PubMed ID: 22410456
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
    Arlen PM; Gulley JL; Tsang KY; Schlom J
    Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress in active specific immunotherapy of prostate cancer.
    Tjoa BA; Murphy GP
    Semin Surg Oncol; 2000; 18(1):80-7. PubMed ID: 10617899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate cancer vaccines.
    Michael A; Relph K; Annels N; Pandha H
    Expert Rev Vaccines; 2013 Mar; 12(3):253-62. PubMed ID: 23496665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer.
    Amato RJ; Stepankiw M
    Future Oncol; 2012 Mar; 8(3):231-7. PubMed ID: 22409460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Provenge: combating prostate cancer with a vengeance?
    Schwaab T; Pili R
    Expert Rev Vaccines; 2011 Aug; 10(8):1113-4. PubMed ID: 21854304
    [No Abstract]   [Full Text] [Related]  

  • 39. Prostate cancer vaccines in combination with additional treatment modalities.
    Uhlman MA; Bing MT; Lubaroff DM
    Immunol Res; 2014 Aug; 59(1-3):236-42. PubMed ID: 24838261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PSA-based vaccines for the treatment of prostate cancer.
    Madan RA; Gulley JL; Arlen PM
    Expert Rev Vaccines; 2006 Apr; 5(2):199-209. PubMed ID: 16608420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.